Sanofi (XBUL:SNW) Debt-to-Equity : 0.33 (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Sanofi Debt-to-Equity?

Sanofi's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was лв19,064 Mil. Sanofi's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was лв28,523 Mil. Sanofi's Total Stockholders Equity for the quarter that ended in Jun. 2024 was лв145,641 Mil. Sanofi's debt to equity for the quarter that ended in Jun. 2024 was 0.33.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Sanofi's Debt-to-Equity or its related term are showing as below:

XBUL:SNW' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.25 Med: 0.32 Max: 0.52
Current: 0.33

During the past 13 years, the highest Debt-to-Equity Ratio of Sanofi was 0.52. The lowest was 0.25. And the median was 0.32.

XBUL:SNW's Debt-to-Equity is ranked worse than
54.6% of 826 companies
in the Drug Manufacturers industry
Industry Median: 0.27 vs XBUL:SNW: 0.33

Sanofi Debt-to-Equity Historical Data

The historical data trend for Sanofi's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Debt-to-Equity Chart

Sanofi Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.44

0.33

0.28

0.25

Sanofi Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Equity	Get a 7-Day Free Trial															0.30	0.28	0.29	0.25	0.33

Competitive Comparison of Sanofi's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Sanofi's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sanofi's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sanofi's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Sanofi's Debt-to-Equity falls into.

Sanofi Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Sanofi's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4709.162	+	32684.022)	/	150287.232
	=	0.25

Sanofi's Debt to Equity Ratio for the quarter that ended in Jun. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19064.178	+	28523.136)	/	145641.105
	=	0.33

Sanofi (XBUL:SNW) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Sanofi Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Sanofi's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Sanofi Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (XBUL:SNW) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

SNYNF:USA SNY:USA SNY:Mexico 1SAN:Italy SANp:UK 0O59:UK SAN:France SNW:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria

Address

46, avenue de la Great Army, Paris, FRA, 75017

Website

https://www.sanofi.com

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, over-the-counter treatments and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 20% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sanofi Headlines

No Headlines